VS vs SKLZ vs GFAI vs MYPS vs DKNG

For growth investors, DraftKings Inc.

(DKNG) is the stronger pick with 27. 0% revenue growth year-over-year, versus -77. 1% for Versus Systems Inc. (VS). Analysts rate DraftKings Inc. (DKNG) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, DraftKings Inc.

(DKNG) delivered a total return of -47. 9%, compared to -99. 9% for Versus Systems Inc. (VS). Over 10 years, the gap is even starker: DKNG returned +157. 3% versus VS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Versus Systems Inc.

(VS) is the lower-risk stock at 0. 88β versus Skillz Inc. 's 2. 57β — meaning SKLZ is approximately 191% more volatile than VS relative to the S&P 500. On balance sheet safety, PLAYSTUDIOS, Inc. (MYPS) carries a lower debt/equity ratio of 3% versus 3% for DraftKings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), DraftKings Inc.

(DKNG) is pulling ahead at 27. 0% versus -77. 1% for Versus Systems Inc. (VS). On earnings-per-share growth, the picture is similar: DraftKings Inc. grew EPS 99. 2% year-over-year, compared to -67. 0% for Skillz Inc.. Over a 3-year CAGR, DKNG leads at 39. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DraftKings Inc.

(DKNG) is the more profitable company, earning 0. 1% net margin versus -70. 6% for Versus Systems Inc. — meaning it keeps 0. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DKNG leads at -0. 3% versus -79. 2% for VS. At the gross margin level — before operating expenses — SKLZ leads at 87. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SKLZ: 931.

5% to $72. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Versus Systems Inc.

(VS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88)). Guardforce AI Co. , Limited (GFAI) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VS: -99. 7%, GFAI: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (VS (Technology) and SKLZ (Technology) and GFAI (Industrials) and MYPS (Technology) and DKNG (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: VS is a small-cap quality compounder stock; SKLZ is a small-cap quality compounder stock; GFAI is a small-cap quality compounder stock; MYPS is a small-cap quality compounder stock; DKNG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.